Skip to main content
GenMont logo

GenMont — Investor Relations & Filings

Ticker · 3164 ISIN · TW0003164000 TW Manufacturing
Open in API
Filings indexed 1,617 across all filing types
Latest filing 2020-07-02 Regulatory Filings
Country TW Taiwan
Listing TW 3164

About GenMont

www.genmont.com.tw

GenMont Biotech Inc. specializes in the research, development, and manufacturing of functional probiotics and postbiotics. The company operates advanced fermentation and production platforms for concentrated fermented milk, lactic acid bacteria powders, and functional microorganism strains. Its product portfolio features patented probiotic solutions targeting diverse health areas, including immune modulation, metabolic health, dental hygiene, digestive function, weight management, and pet wellness. Key proprietary strains include L. paracasei 33 and GMNL-32. GenMont leverages its technology platforms and extensive patent portfolio to deliver scientifically-backed health supplements. Beyond its proprietary brands, the company provides original equipment manufacturing (OEM) services, supporting the global market with high-quality probiotic and postbiotic ingredients certified by international standards.

Recent filings

Filing Released Lang Actions
公告本公司申請股票上櫃轉上市時所出具之承諾事項 暨其後續執行情形
Regulatory Filings Classification · 95% confidence The document is a short announcement (768 characters) from a company named 景岳生物科技股份有限公司 regarding its commitments and subsequent execution related to its application for stock listing transfer from OTC to main board. It references compliance with a Taiwan Stock Exchange regulation and reports on the status of certain audit-related commitments as of a specific date (109/06/30). The document does not contain financial statements or detailed financial data but rather a compliance update and status report. It is not a full financial report, audit report, or earnings release. It is also not a report publication announcement since it contains substantive content about the company's commitments and their execution status. This fits best under Regulatory Filings (RNS), which covers general regulatory announcements and compliance documents that do not fit other categories.
2020-07-02 Chinese
第3次庫藏股執行結果
Transaction in Own Shares Classification · 100% confidence The document is a detailed report on the company's share buyback activity, including the number of shares repurchased, the price range, the total amount spent, and the status of the buyback execution. It includes specific dates and figures related to the repurchase program. This matches the description of a Transaction in Own Shares (POS) filing, which reports on the company's buying back or selling its own shares. The document is not an announcement of a report but contains substantive data about the buyback transaction itself.
2020-07-01 Chinese
公告本公司設立審計委員會
Board/Management Information Classification · 95% confidence The document is a company announcement about the establishment of an audit committee, including details of new appointees and effective dates. It does not contain financial statements, audit opinions, or detailed audit information. It is an announcement of a change in company governance structure, specifically related to board committees. Therefore, it fits best under Board/Management Information (MANG). The document length is short and focused on management changes, not a full report or audit document.
2020-07-01 Chinese
更正公告本公司買回庫藏股期間屆滿執行情形
Transaction in Own Shares Classification · 100% confidence The document is a public announcement from a listed company (3164 景岳) regarding the completion status of its share buyback program. It details the original buyback plan, actual buyback quantities, prices, and reasons for not fully executing the buyback. The content focuses on the company's repurchase of its own shares, including specific figures and dates. This matches the definition of a Transaction in Own Shares (POS) filing, which reports on the company's buyback or sale of its own shares. The document length is short and it is not a report or announcement of a report publication, but a direct disclosure of share repurchase activity.
2020-07-01 Chinese
公告本公司第三屆薪資報酬委員會委員任期屆滿
Board/Management Information Classification · 95% confidence The document is a short announcement regarding the expiration of terms for members of the company's remuneration committee. It details personnel changes but does not contain financial data, audit information, or report content. It is not a full report, earnings release, or presentation. It is a regulatory announcement about board/committee member changes, fitting the category of Board/Management Information (MANG). The document length is short and focused on management changes, not a report publication or certification.
2020-06-30 Chinese
公告本公司第九屆董事會重要決議
Board/Management Information Classification · 100% confidence The document is a short announcement from a company (景岳生物科技股份有限公司) reporting an important resolution from its ninth board meeting, specifically the re-election of the chairman. The content focuses on board decisions and management changes, with no financial data or detailed report content. The document length is only 589 characters, indicating it is a brief announcement rather than a full report. This fits the category of Board/Management Information (MANG), which covers announcements of changes in the company's board or senior management.
2020-06-30 Chinese

Browse filings by year

14 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.